NCT01807455已完成4 期
An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Galderma R&D
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Evaluation of Acne Scarring and the Surrounding Skin Using the Global Aesthetic Improvement Scale
研究概览
简要总结
The purpose of this study is to demonstrate the efficacy and safety of Restylane Vital Lidocaine when acne scars are treated
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 25 to 45 years.
- •Caucasian with Fitzpatrick skin type I-III.
- •Must be cooperative and willing to comply with the instructions and procedures.
- •Provision of signed and dated informed consent to participate in the study.
- •Presence of depressed facial atrophic acne scars with a diameter of <4 mm according to at least SCAR-S score 3 category moderate (i.e. more than half of the face involved).
排除标准
- •Icepick scarring or atrophic scars with a diameter of ≥4 mm covering more than 25% of the face.
- •Active acne with inflammatory component.
- •Post-surgical scars in the face.
- •History of keloid formation or hypertrophic scars.
- •Use of isotretinoin within 12 months of the baseline visit.
- •Use of per oral or topical (facial) substances containing retinoids, bensoyl peroxide, alpha-hydroxy acid at a concentration above 10% or beta-hydroxy acid at a concentration above 2% or antibiotics within four months of the baseline visit.
- •Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation (e.g. aspirin or other nonsteroidal anti-inflammatory drugs [NSAIDs]), Omega-3 or vitamin E seven days before the injection, or a history of bleeding disorders.
- •Use of anti-inflammatory agents seven days before the injection.
- •History of radiation or skin tumours including actinic keratosis in the face.
- •Active skin disease, inflammation or related conditions, such as infection, perioral dermatitis, seborrheic eczema and rosacea in the face.
- •History of or active collagen diseases or autoimmune diseases such as systemic lupus erythematous, rheumatic arthritis, skin or systemic sclerosis.
- •Previous hypersensitivity to HA.
- •Previous hypersensitivity to lidocaine or other amide-type anaesthetics.
- •Concomitant treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids within 3 months of the baseline visit. (Inhaled corticoids are not an exclusion criterion).
- •Presence of facial hair that may interfere with efficacy evaluations.
- •Previous tissue augmenting therapy or revitalization treatment in the treatment area with HA or collagen, within 12 months of the baseline visit.
- •Permanent implant or treatment with fillers based on other material than HA or collagen in the treatment area.
- •Laser, e.g. carbon dioxide and Fraxel, dermabrasion or facial light therapy, e.g. IPL, in the treatment area within 12 months of the baseline visit.
- •Chemical peeling in the treatment area within 6 months of the baseline visit.
- •Previous surgery in the treatment area.
- •Nicotine use within 6 months before the baseline visit.
- •Pregnancy or breast feeding.
- •Participation in any other clinical study within 30 days before inclusion.
- •Any medical condition that in the opinion of the investigator makes the subject unsuitable for inclusion (e.g. severe chronic disease, epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction).
- •Other condition preventing the subject from entering the study in the investigator's opinion, e.g. subjects not likely to avoid other facial cosmetic treatments, subjects anticipated to be unreliable or incapable of understanding the study assessment or unrealistic expectations of treatment result.
- •Study staff or close relative of study staff (e.g. parents, children, siblings and spouse).
结局指标
主要结局
Evaluation of Acne Scarring and the Surrounding Skin Using the Global Aesthetic Improvement Scale
时间窗: 36 weeks
Percentage of improved subjects at 36 weeks after first treatment session assessed using Subject GAIS. Scale range is Worse, No Change, Somewhat Improved, Much Improved and Very Much Improved. Alternatives Somewhat Improved to Very Much Improved are considered an improvement, i.e. a better outcome.
次要结局
- Evaluation of Skin Quality and Overall Satisfaction Using a Subject Satisfaction Questionnaire(36 weeks)
- Assessment of Local Tolerability After Treatment(14 days)
- Evaluation of Acne Scarring Using the Scale for Acne Scar Severity (SCAR-S)(36 weeks)
- Adverse Event Reporting During the Study(36 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne ScarsHealthy VolunteersNCT03127384Galderma R&D49
已完成
不适用
Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian PopulationHealthy VolunteersNCT02565784Galderma R&D100
已完成
不适用
Study to Evaluate Restylane Vital Light Using an Injector DeviceAestheticsNCT01412190Galderma R&D30
已完成
不适用
Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin ProfileChin AugmentationChin RetrusionNCT05777759Galderma R&D175
已完成
不适用
Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial FoldsNasolabial Folds in Chinese PopulationNCT02432742Galderma R&D100